EPCLUSA is indicated for the treatment of adults with chronic hepatitis C virus (HCV) GT 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Formulary information provided by Fingertip Formulary® and is current as of . Because formularies do change and many health plans offer more than one formulary, please check with the health plan directly to confirm coverage for individual patients.
*Coverage status may vary by genotype.
Exclusive = is on formulary while other direct-acting antivirals (DAAs) are not, has a lower tier status than other DAAs, or is required in a step therapy process vs other DAAs.
Preferred = shares the lowest tier status with at least one direct-acting antiviral.
Non-Preferred = another direct-acting antiviral has a lower tier status or is required in a step therapy process.
Not Available = formulary status information not available.
Not Covered = the product is not on the preferred drug list for the health plan.
Sofosbuvir/velpatasvir (authorized generic of EPCLUSA) is marketed by Asegua Therapeutics LLC, an affiliate of Gilead.
Click here for patient support services, which may assist in identifying coverage options for your patients.
The references to company/plan names listed do not, in any manner, imply an endorsement of EPCLUSA or any other products by the referenced companies/plans.
Placement on the formulary is not intended to imply any claims regarding safety or efficacy of the products referenced.
A co-pay coupon may help eligible patients reduce out-of-pocket costs of Gilead treatment.
Support Path can help patients understand insurance coverage and financial support options to get started on treatment.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV COINFECTED PATIENTS
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with EPCLUSA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Warnings and Precautions
Consult the full Prescribing Information for EPCLUSA for more information on potentially significant drug interactions, including clinical comments.
Please see full Prescribing Information for EPCLUSA, including BOXED WARNING.